<DOC>
	<DOCNO>NCT01561690</DOCNO>
	<brief_summary>This Phase 2 study , involve 6-week treatment period , design evaluate effectiveness investigational study drug ARRY-502 treating mild moderate persistent asthma , evaluate safety drug . Approximately 180 patient US enrol study .</brief_summary>
	<brief_title>A Study ARRY-502 Patients With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Key Documented history bronchial asthma diagnose least 6 month prior study start prior age 40 year . Body mass index ( BMI ) 18 35 inclusive . An ACQ score ≥ 1.5 specified time point prior first dose study drug . A best prebronchodilator FEV1 60 % 85 % predict normal value change best postbronchodilator FEV1 ≥ 12 % ≥ 200 mL specify time point prior first dose study drug . Additional criterion exist . Key Evidence aspirinsensitive asthma . Preexisting lung disease asthma . Clinically significant dermatologic , hematological , renal , endocrine , pulmonary ( asthma ) , gastrointestinal , cardiovascular , hepatic , neurologic , ophthalmologic , musculoskeletal immunologic disease ( except allergic disease asthma ) uncontrolled despite treatment likely opinion Investigator require change therapy study . Patients current past history cancer within 5 year prior study start except treated basal cell squamous cell carcinoma skin , ductal carcinoma situ breast cervical carcinoma situ . Any history serious illness require hospitalization within 6 month prior study start . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis B and/or active hepatitis C. A positive test drug alcohol , unless positive drug screen associate prescribed medication approve Medical Monitor . Smoking ( tobacco marijuana ) within 6 month prior study start and/or smoke history &gt; 10 packs/year . Blood donation ≥ 1 pint ( 473 mL ) within 8 week prior first dose study drug . Previous treatment ARRY502 . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>